Anacor Pharmaceuticals Inc  

(Public, NASDAQ:ANAC)   Watch this stock  
Find more results for ANAC
33.41
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 13.19 - 37.45
Open     -
Vol / Avg. 0.00/542,768.00
Mkt cap 1.43B
P/E 32.13
Div/yield     -
EPS 1.04
Shares 42.90M
Beta 1.63
Inst. own 98%
Mar 11, 2015
Q4 2014 Anacor Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Nov 13, 2014
Anacor Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 6, 2014
Q3 2014 Anacor Pharmaceuticals Inc Earnings Call
Nov 6, 2014
Q3 2014 Anacor Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -792.47% 492.02%
Operating margin -765.49% 529.00%
EBITD margin - -287.18%
Return on average assets -84.87% 75.94%
Return on average equity -169.77% 134.29%
Employees 79 -
CDP Score - -

Address

1020 East Meadow Circle
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Anacor Pharmaceuticals Inc is a United States-based biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company�s product candidates include topically administered dermatologic compounds-tavaborole (formerly AN2690), a topical antifungal for the treatment of onychomycosis, and AN2728, a topical anti-inflammatory for the treatment of atopic dermatitis and psoriasis. In addition, it is engaged in the development of other wholly-owned clinical product candidates, AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. The Company's clinical pipeline also includes internally developed topical and systemic boron-based compounds in development.

Officers and directors

Paul L. Berns Chairman of the Board, President, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Geoffrey M. Parker Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Vincent P. Ippolito Executive Vice President, Chief Commercial Officer
Age: 55
Bio & Compensation  - Reuters
Sanjay Chanda Ph.D. Senior Vice President - Drug Development
Age: 49
Bio & Compensation  - Reuters
Kirk R. Maples Ph.D. Senior Vice President - Program Management
Age: 55
Bio & Compensation  - Reuters
Jacob J. Plattner Ph.D. Senior Vice President - Research
Age: 67
Bio & Compensation  - Reuters
Carmen R. Rodriguez Ph.D. Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 65
Bio & Compensation  - Reuters
Lee T. Zane M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Age: 44
Bio & Compensation  - Reuters
William J. Rieflin Lead Independent Director
Age: 54
Bio & Compensation  - Reuters
Anders D. Hove M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters